23andMe closes out 2020 with $82.5M in funding
DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.
INVEST Precision Medicine Pitch Perfect winner spotlight: TrialSpark
Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity's virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.
BridgeBio Pharma raises $299.2M in financing round
The company sources product candidates from academic and commercial research and then launches subsidiary companies to develop them.
Digital startup focused on women’s and family health secures $27M
The company, Maven, raised funding from investors including Sequoia Capital, Oak HC/FT, 14W, Female Founders Fund and Spring Mountain Capital.
23andMe hears the call of therapeutics
Through its popular consumer portal, the Silicon Valley company has recruited thousands of study participants to identify genetic determinants of depression, heart disease, cancer, immunological disorders and skin diseases.
Telcare nabs $32M for mobile glucose monitoring
Telcare, which has developed mobile applications to monitor blood glucose levels for diabetics, has raised $32.5 million in a Series C round. The Bethesda-based digital health company, which also developed a HIPAA-compliant cloud for data storage, was founded in 2009. Funding was led by Norwest Venture Partners, with additional help from Mosaic Health Solutions and […]
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Sequoia Capital partner to lead Ohio Department of Development (for $1)
Newly inaugurated Gov. John Kasich has appointed friend, campaign contributor and Sequoia Capital partner Mark Kvamme as the interim director of the Ohio Department of Development.